Novocure Ltd (NASDAQ: NVCR) Stock Competitors & Peer Comparison
See NVCR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NVCR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVCR | $14.07 | -2.36% | 1.6B | -10.82 | -$1.30 | N/A |
| ABT | $104.89 | +0.20% | 181.5B | 20.13 | $5.21 | +2.40% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.75 | -0.73% | 121.2B | 17.14 | $5.53 | +3.02% |
| SYK | $294.66 | +0.49% | 113B | 22.01 | $13.39 | +1.20% |
| BSX | $44.39 | +0.57% | 64.3B | 14.32 | $3.10 | N/A |
| EW | $86.60 | -1.70% | 49.9B | 32.07 | $2.70 | N/A |
| DXCM | $86.04 | -1.90% | 32.5B | 33.74 | $2.55 | N/A |
| GEHC | $69.57 | -1.11% | 31.4B | 15.26 | $4.56 | +0.20% |
| PHG | $25.74 | +0.98% | 24.9B | 14.72 | $1.75 | +3.84% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
NVCR vs ABT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ABT has a market cap of 181.5B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ABT trades at $104.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ABT's P/E ratio is 20.13. In terms of profitability, NVCR's ROE is -0.44%, compared to ABT's ROE of +0.11%. Regarding short-term risk, NVCR is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
NVCR vs BSX-PA Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NVCR's ROE is -0.44%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NVCR is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
NVCR vs MDT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, MDT has a market cap of 121.2B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while MDT trades at $94.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas MDT's P/E ratio is 17.14. In terms of profitability, NVCR's ROE is -0.44%, compared to MDT's ROE of +0.11%. Regarding short-term risk, NVCR is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
NVCR vs SYK Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SYK has a market cap of 113B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SYK trades at $294.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SYK's P/E ratio is 22.01. In terms of profitability, NVCR's ROE is -0.44%, compared to SYK's ROE of +0.16%. Regarding short-term risk, NVCR is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
NVCR vs BSX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BSX has a market cap of 64.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BSX trades at $44.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BSX's P/E ratio is 14.32. In terms of profitability, NVCR's ROE is -0.44%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NVCR is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
NVCR vs EW Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, EW has a market cap of 49.9B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while EW trades at $86.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas EW's P/E ratio is 32.07. In terms of profitability, NVCR's ROE is -0.44%, compared to EW's ROE of +0.10%. Regarding short-term risk, NVCR is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
NVCR vs DXCM Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, DXCM has a market cap of 32.5B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while DXCM trades at $86.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas DXCM's P/E ratio is 33.74. In terms of profitability, NVCR's ROE is -0.44%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, NVCR is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
NVCR vs GEHC Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, GEHC has a market cap of 31.4B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while GEHC trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas GEHC's P/E ratio is 15.26. In terms of profitability, NVCR's ROE is -0.44%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, NVCR is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
NVCR vs PHG Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PHG has a market cap of 24.9B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PHG trades at $25.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PHG's P/E ratio is 14.72. In terms of profitability, NVCR's ROE is -0.44%, compared to PHG's ROE of +0.10%. Regarding short-term risk, NVCR is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
NVCR vs ZBH Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ZBH trades at $94.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ZBH's P/E ratio is 11.20. In terms of profitability, NVCR's ROE is -0.44%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NVCR is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
NVCR vs ABMD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NVCR's ROE is -0.44%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NVCR is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
NVCR vs PEN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PEN trades at $320.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PEN's P/E ratio is 83.79. In terms of profitability, NVCR's ROE is -0.44%, compared to PEN's ROE of +0.11%. Regarding short-term risk, NVCR is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
NVCR vs SWAV Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NVCR's ROE is -0.44%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NVCR is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
NVCR vs SNN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SNN trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SNN's P/E ratio is 19.62. In terms of profitability, NVCR's ROE is -0.44%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NVCR is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
NVCR vs ALGN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ALGN trades at $147.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ALGN's P/E ratio is 13.43. In terms of profitability, NVCR's ROE is -0.44%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, NVCR is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
NVCR vs GMED Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while GMED trades at $76.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas GMED's P/E ratio is 17.27. In terms of profitability, NVCR's ROE is -0.44%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NVCR is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
NVCR vs PODD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PODD trades at $141.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PODD's P/E ratio is 24.04. In terms of profitability, NVCR's ROE is -0.44%, compared to PODD's ROE of +0.27%. Regarding short-term risk, NVCR is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check PODD's competition here
Glaukos Corporation (NYSE: GKOS)
NVCR vs GKOS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while GKOS trades at $164.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas GKOS's P/E ratio is -191.66. In terms of profitability, NVCR's ROE is -0.44%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, NVCR is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
NVCR vs BIO-B Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BIO-B has a market cap of 9.6B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BIO-B trades at $355.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BIO-B's P/E ratio is -62.58. In terms of profitability, NVCR's ROE is -0.44%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, NVCR is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
NVCR vs BIO Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BIO trades at $353.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BIO's P/E ratio is 38.12. In terms of profitability, NVCR's ROE is -0.44%, compared to BIO's ROE of +0.03%. Regarding short-term risk, NVCR is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
NVCR vs MASI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas MASI's P/E ratio is 44.43. In terms of profitability, NVCR's ROE is -0.44%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NVCR is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
NVCR vs BRKR Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BRKR has a market cap of 8.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BRKR trades at $54.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BRKR's P/E ratio is 27.54. In terms of profitability, NVCR's ROE is -0.44%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, NVCR is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
NVCR vs BRKRP Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BRKRP has a market cap of 8.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BRKRP trades at $405.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BRKRP's P/E ratio is 220.46. In terms of profitability, NVCR's ROE is -0.44%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, NVCR is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
NVCR vs HAE Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while HAE trades at $118.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas HAE's P/E ratio is 23.62. In terms of profitability, NVCR's ROE is -0.44%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NVCR is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
NVCR vs NARI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas NARI's P/E ratio is -59.24. In terms of profitability, NVCR's ROE is -0.44%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NVCR is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
NVCR vs ITGR Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ITGR trades at $126.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ITGR's P/E ratio is 19.96. In terms of profitability, NVCR's ROE is -0.44%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, NVCR is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
NVCR vs LIVN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while LIVN trades at $77.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas LIVN's P/E ratio is 18.43. In terms of profitability, NVCR's ROE is -0.44%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, NVCR is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
NVCR vs IRTC Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while IRTC trades at $108.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas IRTC's P/E ratio is -252.70. In terms of profitability, NVCR's ROE is -0.44%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, NVCR is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
NVCR vs NEOG Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while NEOG trades at $11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas NEOG's P/E ratio is 42.18. In terms of profitability, NVCR's ROE is -0.44%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, NVCR is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
NVCR vs TMDX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while TMDX trades at $70.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas TMDX's P/E ratio is 35.93. In terms of profitability, NVCR's ROE is -0.44%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, NVCR is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
NVCR vs UFPT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while UFPT trades at $291.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas UFPT's P/E ratio is 29.79. In terms of profitability, NVCR's ROE is -0.44%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NVCR is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
NVCR vs NUVA Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NVCR's ROE is -0.44%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NVCR is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check NUVA's competition here
AxoGen, Inc. (NASDAQ: AXGN)
NVCR vs AXGN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, AXGN has a market cap of 2B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while AXGN trades at $34.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas AXGN's P/E ratio is 91.13. In terms of profitability, NVCR's ROE is -0.44%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, NVCR is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
NVCR vs INSP Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while INSP trades at $68.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas INSP's P/E ratio is 30.30. In terms of profitability, NVCR's ROE is -0.44%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NVCR is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
NVCR vs BFLY Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BFLY trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BFLY's P/E ratio is -30.21. In terms of profitability, NVCR's ROE is -0.44%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, NVCR is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
NVCR vs ESTA Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ESTA trades at $59.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ESTA's P/E ratio is -46.96. In terms of profitability, NVCR's ROE is -0.44%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, NVCR is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check ESTA's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
NVCR vs ATEC Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ATEC trades at $10.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ATEC's P/E ratio is -174.33. In terms of profitability, NVCR's ROE is -0.44%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, NVCR is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
NVCR vs CNMD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CNMD trades at $46.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CNMD's P/E ratio is 10.27. In terms of profitability, NVCR's ROE is -0.44%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, NVCR is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check CNMD's competition here
Picard Medical, Inc. (AMEX: PMI)
NVCR vs PMI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PMI has a market cap of 1.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PMI trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PMI's P/E ratio is -10.70. In terms of profitability, NVCR's ROE is -0.44%, compared to PMI's ROE of -9.31%. Regarding short-term risk, NVCR is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check PMI's competition here
Heska Corporation (NASDAQ: HSKA)
NVCR vs HSKA Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NVCR's ROE is -0.44%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NVCR is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
NVCR vs AVNS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas AVNS's P/E ratio is 27.77. In terms of profitability, NVCR's ROE is -0.44%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NVCR is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
NVCR vs ENOV Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ENOV trades at $19.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ENOV's P/E ratio is 5.62. In terms of profitability, NVCR's ROE is -0.44%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, NVCR is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
NVCR vs TNDM Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while TNDM trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas TNDM's P/E ratio is -17.46. In terms of profitability, NVCR's ROE is -0.44%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, NVCR is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check TNDM's competition here
IRadimed Corporation (NASDAQ: IRMD)
NVCR vs IRMD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while IRMD trades at $88.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas IRMD's P/E ratio is 44.36. In terms of profitability, NVCR's ROE is -0.44%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NVCR is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
NVCR vs SILK Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SILK's P/E ratio is -18.96. In terms of profitability, NVCR's ROE is -0.44%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NVCR is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
NVCR vs FNA Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas FNA's P/E ratio is -19.83. In terms of profitability, NVCR's ROE is -0.44%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NVCR is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check FNA's competition here
Artivion, Inc. (NYSE: AORT)
NVCR vs AORT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while AORT trades at $21.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas AORT's P/E ratio is 36.28. In terms of profitability, NVCR's ROE is -0.44%, compared to AORT's ROE of -0.01%. Regarding short-term risk, NVCR is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check AORT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
NVCR vs LMRI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while LMRI trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas LMRI's P/E ratio is -20.99. In terms of profitability, NVCR's ROE is -0.44%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NVCR is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check LMRI's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
NVCR vs IART Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, IART has a market cap of 1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while IART trades at $13.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas IART's P/E ratio is 5.60. In terms of profitability, NVCR's ROE is -0.44%, compared to IART's ROE of -0.01%. Regarding short-term risk, NVCR is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
NVCR vs PRCT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PRCT trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PRCT's P/E ratio is -9.06. In terms of profitability, NVCR's ROE is -0.44%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, NVCR is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check PRCT's competition here
CeriBell, Inc. (NASDAQ: CBLL)
NVCR vs CBLL Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CBLL has a market cap of 960.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CBLL trades at $25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CBLL's P/E ratio is -14.22. In terms of profitability, NVCR's ROE is -0.44%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, NVCR is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
NVCR vs BVS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BVS has a market cap of 909.5M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BVS trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BVS's P/E ratio is 17.52. In terms of profitability, NVCR's ROE is -0.44%, compared to BVS's ROE of +0.28%. Regarding short-term risk, NVCR is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
NVCR vs SIBN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SIBN has a market cap of 882M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SIBN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SIBN's P/E ratio is -57.88. In terms of profitability, NVCR's ROE is -0.44%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, NVCR is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
NVCR vs CSII Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CSII's P/E ratio is -20.83. In terms of profitability, NVCR's ROE is -0.44%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NVCR is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
NVCR vs AHCO Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, AHCO has a market cap of 820.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while AHCO trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas AHCO's P/E ratio is 12.29. In terms of profitability, NVCR's ROE is -0.44%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, NVCR is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
NVCR vs INMD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, INMD has a market cap of 814.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while INMD trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas INMD's P/E ratio is 9.83. In terms of profitability, NVCR's ROE is -0.44%, compared to INMD's ROE of +0.12%. Regarding short-term risk, NVCR is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
NVCR vs VREX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, VREX has a market cap of 781.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while VREX trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas VREX's P/E ratio is 19.38. In terms of profitability, NVCR's ROE is -0.44%, compared to VREX's ROE of +0.05%. Regarding short-term risk, NVCR is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check VREX's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
NVCR vs BBNX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BBNX has a market cap of 737.4M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BBNX trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BBNX's P/E ratio is -9.93. In terms of profitability, NVCR's ROE is -0.44%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, NVCR is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check BBNX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
NVCR vs CTKB Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CTKB has a market cap of 682.4M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CTKB trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CTKB's P/E ratio is -27.81. In terms of profitability, NVCR's ROE is -0.44%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, NVCR is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
NVCR vs SRDX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NVCR's ROE is -0.44%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NVCR is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check SRDX's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
NVCR vs AVR Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, AVR has a market cap of 589.6M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while AVR trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas AVR's P/E ratio is -3.12. In terms of profitability, NVCR's ROE is -0.44%, compared to AVR's ROE of -0.78%. Regarding short-term risk, NVCR is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check AVR's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
NVCR vs APEN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas APEN's P/E ratio is -9.43. In terms of profitability, NVCR's ROE is -0.44%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NVCR is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
NVCR vs KIDS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, KIDS has a market cap of 571.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while KIDS trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas KIDS's P/E ratio is -18.56. In terms of profitability, NVCR's ROE is -0.44%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, NVCR is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check KIDS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
NVCR vs PACB Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PACB has a market cap of 537.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PACB trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PACB's P/E ratio is -4.22. In terms of profitability, NVCR's ROE is -0.44%, compared to PACB's ROE of -49.62%. Regarding short-term risk, NVCR is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check PACB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
NVCR vs ZIMV Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NVCR's ROE is -0.44%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, NVCR is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
NVCR vs TCMD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, TCMD has a market cap of 510.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while TCMD trades at $22.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas TCMD's P/E ratio is 20.85. In terms of profitability, NVCR's ROE is -0.44%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, NVCR is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check TCMD's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
NVCR vs SSII Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SSII has a market cap of 507.2M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SSII trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SSII's P/E ratio is -42.17. In terms of profitability, NVCR's ROE is -0.44%, compared to SSII's ROE of -0.27%. Regarding short-term risk, NVCR is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
NVCR vs DCTH Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, DCTH has a market cap of 488.4M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while DCTH trades at $14.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas DCTH's P/E ratio is 1407.50. In terms of profitability, NVCR's ROE is -0.44%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, NVCR is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check DCTH's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
NVCR vs SGHT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SGHT has a market cap of 456.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SGHT trades at $8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SGHT's P/E ratio is -14.79. In terms of profitability, NVCR's ROE is -0.44%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, NVCR is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
NVCR vs CERS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CERS has a market cap of 437.3M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CERS trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CERS's P/E ratio is -72.09. In terms of profitability, NVCR's ROE is -0.44%, compared to CERS's ROE of -0.10%. Regarding short-term risk, NVCR is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
NVCR vs NPCE Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, NPCE has a market cap of 420.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while NPCE trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas NPCE's P/E ratio is -21.47. In terms of profitability, NVCR's ROE is -0.44%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, NVCR is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
NVCR vs SENS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SENS has a market cap of 410.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SENS trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SENS's P/E ratio is -3.48. In terms of profitability, NVCR's ROE is -0.44%, compared to SENS's ROE of -1.66%. Regarding short-term risk, NVCR is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
NVCR vs OFIX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, OFIX has a market cap of 379.2M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while OFIX trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas OFIX's P/E ratio is -6.11. In terms of profitability, NVCR's ROE is -0.44%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, NVCR is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
NVCR vs CV Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CV has a market cap of 347.5M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CV trades at $6.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CV's P/E ratio is -10.37. In terms of profitability, NVCR's ROE is -0.44%, compared to CV's ROE of -1.78%. Regarding short-term risk, NVCR is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
NVCR vs RCEL Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, RCEL has a market cap of 324M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while RCEL trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas RCEL's P/E ratio is -9.06. In terms of profitability, NVCR's ROE is -0.44%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, NVCR is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check RCEL's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
NVCR vs SMLR Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NVCR's ROE is -0.44%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, NVCR is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NVCR vs CLPT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CLPT has a market cap of 276.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CLPT trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CLPT's P/E ratio is -7.69. In terms of profitability, NVCR's ROE is -0.44%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, NVCR is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
NVCR vs INFU Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, INFU has a market cap of 266.9M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while INFU trades at $13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas INFU's P/E ratio is 32.68. In terms of profitability, NVCR's ROE is -0.44%, compared to INFU's ROE of +0.15%. Regarding short-term risk, NVCR is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check INFU's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NVCR vs TMCI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, TMCI has a market cap of 251.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while TMCI trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas TMCI's P/E ratio is -4.12. In terms of profitability, NVCR's ROE is -0.44%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, NVCR is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
NVCR vs CATX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, CATX has a market cap of 247.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while CATX trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas CATX's P/E ratio is -1.63. In terms of profitability, NVCR's ROE is -0.44%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NVCR is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check CATX's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
NVCR vs MGRM Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NVCR's ROE is -0.44%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, NVCR is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
NVCR vs ELMD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ELMD has a market cap of 228.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ELMD trades at $27.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ELMD's P/E ratio is 21.02. In terms of profitability, NVCR's ROE is -0.44%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, NVCR is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
NVCR vs NVRO Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NVCR's ROE is -0.44%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NVCR is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
NVCR vs TLSI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, TLSI has a market cap of 223.5M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while TLSI trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas TLSI's P/E ratio is -2.16. In terms of profitability, NVCR's ROE is -0.44%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, NVCR is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check TLSI's competition here
Quantum-Si incorporated (NASDAQ: QSI)
NVCR vs QSI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, QSI has a market cap of 222.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while QSI trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas QSI's P/E ratio is -2.43. In terms of profitability, NVCR's ROE is -0.44%, compared to QSI's ROE of -0.47%. Regarding short-term risk, NVCR is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
NVCR vs PROF Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, PROF has a market cap of 219.6M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while PROF trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas PROF's P/E ratio is -6.13. In terms of profitability, NVCR's ROE is -0.44%, compared to PROF's ROE of -0.56%. Regarding short-term risk, NVCR is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check PROF's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
NVCR vs BSGM Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NVCR's ROE is -0.44%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, NVCR is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
NVCR vs RXST Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, RXST has a market cap of 187.6M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while RXST trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas RXST's P/E ratio is -3.99. In terms of profitability, NVCR's ROE is -0.44%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NVCR is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check RXST's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
NVCR vs MDGS Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NVCR's ROE is -0.44%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NVCR is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
NVCR vs INGN Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, INGN has a market cap of 165.9M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while INGN trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas INGN's P/E ratio is -6.87. In terms of profitability, NVCR's ROE is -0.44%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NVCR is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
NVCR vs QIPT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NVCR's ROE is -0.44%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, NVCR is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
NVCR vs FOCL Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, FOCL has a market cap of 154.8M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while FOCL trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas FOCL's P/E ratio is -3.99. In terms of profitability, NVCR's ROE is -0.44%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, NVCR is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
NVCR vs STIM Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, STIM has a market cap of 143.6M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while STIM trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas STIM's P/E ratio is -4.28. In terms of profitability, NVCR's ROE is -0.44%, compared to STIM's ROE of -1.51%. Regarding short-term risk, NVCR is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
NVCR vs QTRX Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, QTRX has a market cap of 135.7M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while QTRX trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas QTRX's P/E ratio is -1.13. In terms of profitability, NVCR's ROE is -0.44%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, NVCR is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
NVCR vs OWLT Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, OWLT has a market cap of 120.1M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while OWLT trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas OWLT's P/E ratio is -29.36. In terms of profitability, NVCR's ROE is -0.44%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, NVCR is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
NVCR vs ICAD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NVCR's ROE is -0.44%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NVCR is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
NVCR vs HJLI Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas HJLI's P/E ratio is N/A. In terms of profitability, NVCR's ROE is -0.44%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, NVCR is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
NVCR vs ASXC Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NVCR's ROE is -0.44%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, NVCR is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for NVCR.Check ASXC's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
NVCR vs LUCD Comparison October 2026
Novocure Ltd (NASDAQ: NVCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCR stands at 1.6B. In comparison, LUCD has a market cap of 91.3M. Regarding current trading prices, NVCR is priced at $14.07 on the NASDAQ, while LUCD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCR currently has a P/E ratio of -10.82, whereas LUCD's P/E ratio is -1.29. In terms of profitability, NVCR's ROE is -0.44%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, NVCR is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for NVCR.Check LUCD's competition here